BT-11

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530322

CAS#: 1912399-75-7 (free base)

Description: BT-11 is an orally active and selective LANCL2 modulator. BT-11 has demonstrated therapeutic efficacy in 3 validated mouse models of colitis at doses as low as 8 mg/kg/d. BT-11 at high doses has an excellent safety profile up to 1000 mg/kg/day. BT-11 protects from IBD by targeting LANCL2. BT-11 has potential to be a safe and effective orally active therapeutic for IBD. Lanthionine synthetase C-like 2 (LANCL2), a novel therapeutic target for inflammatory and autoimmune diseases and diabetes, exerts anti-inflammatory and insulin-sensitizing effects.


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-03-30. Prices are subject to change without notice.

BT-11 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 530322
Name: BT-11
CAS#: 1912399-75-7 (free base)
Chemical Formula: C30H24N8O2
Exact Mass: 528.2022
Molecular Weight: 528.576
Elemental Analysis: C, 68.17; H, 4.58; N, 21.20; O, 6.05


Related CAS #: 1912399-91-7 (HCl)   1912399-75-7 (free base)    

Synonym: BT-11; BT 11; BT11.

IUPAC/Chemical Name: piperazine-1,4-diylbis((6-(1H-benzo[d]imidazol-2-yl)pyridin-2-yl)methanone)

InChi Key: MVHWZNBAQIGPOQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C30H24N8O2/c39-29(25-13-5-11-23(31-25)27-33-19-7-1-2-8-20(19)34-27)37-15-17-38(18-16-37)30(40)26-14-6-12-24(32-26)28-35-21-9-3-4-10-22(21)36-28/h1-14H,15-18H2,(H,33,34)(H,35,36)

SMILES Code: O=C(N1CCN(C(C2=NC(C3=NC4=CC=CC=C4N3)=CC=C2)=O)CC1)C5=NC(C6=NC7=CC=CC=C7N6)=CC=C5


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


Additional Information

Related CAS#
1912399-91-7 (BT-11 dihydrochloride)
1912399-75-7 (BT-11 free base)

Inflammatory bowel disease (IBD), a chronic recurring disease of the gastrointestinal (GI) tract, afflicts over 1 million people in North America and 4 million worldwide. This widespread and debilitating autoimmune disease results in decreased quality of life and significant health care-related costs. IBD comprises two clinical manifestations: ulcerative colitis (UC) and Crohn’s disease. Both pathologies are characterized by uncontrolled chronic inflammation in the GI tract triggered by an unbalanced, pro-inflammatory immune response to the commensal gut microbiota. Current therapies for IBD, such as anti-TNF-α biologics, are modestly successful for the long-term management of the disease and have significant adverse side effects, including infection, cancer, and death.


References

1: Bissel P, Boes K, Hinckley J, Jortner BS, Magnin-Bissel G, Werre SR, Ehrich M, Carbo A, Philipson C, Hontecillas R, Philipson N, Gandour RD, Bassaganya-Riera J. Exploratory Studies With BT-11: A Proposed Orally Active Therapeutic for Crohn's Disease. Int J Toxicol. 2016 Sep;35(5):521-9. doi: 10.1177/1091581816646356. PubMed PMID: 27230993; PubMed Central PMCID: PMC5033715.

2. Adria Carbo, Richard D. Gandour, Raquel Hontecillas, Noah Philipson, Aykut Uren, and Josep Bassaganya-Riera. An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease
Publication Date (Web): November 4, 2016 (Article). DOI: 10.1021/acs.jmedchem.6b00412